Seeking Alpha

Acorda Therapeutics (ACOR), a developer of drugs for treating neurological disorders, gains...

Acorda Therapeutics (ACOR), a developer of drugs for treating neurological disorders, gains 14.6% after reporting Q3 revenue of $93M and EPS of $0.40; while the latter missed by $0.33, the former beat by $2.2M, and investors appear reassured by positive comments regarding market acceptance of the company's Ampyra MS drug, made in partnership with ELN.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs